Please login to the form below

Not currently logged in
Email:
Password:

psychiatric diseases

This page shows the latest psychiatric diseases news and features for those working in and with pharma, biotech and healthcare.

Novartis plans digital therapeutics for schizophrenia and MS

Novartis plans digital therapeutics for schizophrenia and MS

Jay Bradner, president of the Novartis Institutes for Biomedical Research, said: "Psychiatric and neurodegenerative diseases place a heavy physical, mental and economic burden on patients and their families. ... With widespread adoption of digital devices

Latest news

  • Boehringer crowdsources psychiatric research team Boehringer crowdsources psychiatric research team

    The team of neuroscientists was identified by Boehringer and BioMed X via a crowdsourcing competition tasked with exploring the 'most promising solution approaches' to psychiatric diseases. ... Last year, Boehringer Ingelheim entered into a psychiatric

  • Boehringer pledges €11bn to fund R&D drive Boehringer pledges €11bn to fund R&D drive

    All four collaborations are focusing on research into inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, looking at new therapeutic targets as well as biomarkers that can be ... In addition, the company signed a deal with Circuit

  • AZ names leader for new ‘virtual’ neuroscience research unit

    of neurological diseases including Alzheimer's, neuropathic pain, depression and Parkinson's. “ ... While many companies have exited or scaled back efforts in this high-risk area, we will step up the search for new medicines to help people with

  • John Thievon named president of Dey Pharma

    As president of Dey Pharma, Thievon will drive the company's focus on medicines to treat respiratory diseases, severe allergic reactions and psychiatric disorders.

  • GSK/Neurocrine depression drug fails

    Neurocrine and GSK signed a worldwide research, development and commercialisation agreement for Corticotropin Releasing Factor Receptor Antagonists for psychiatric, neurological and gastrointestinal diseases in 2001.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    Product portfolio covering rare diseases in haematology, immunology, oncology; cash and stock deal at 37.5% share price premium. ... 280. Arena / Boehringer Ingelheim. Joint research collaboration. Development of treatments for psychiatric diseases and

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Sanofi appoints Diane Souza and Thomas Südhof Sanofi appoints Diane Souza and Thomas Südhof

    Before joining Stanford, he spent 25 years at the University of Texas as chairman of the department of neuroscience researching neuro-degenerative and neuro-psychiatric diseases.

  • MedDay appoints former Sanofi VP to board MedDay appoints former Sanofi VP to board

    Goupit said: “ I strongly believe that MedDay's product pipeline and its research platform, SPECMET, could have a major impact on the treatment of neurological and psychiatric diseases.”.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • emotive. expands Medical Writing and Client Services teams

    With over 9 years’ experience in medical communications, Aki Okazaki who is joining as an Associate Director, has worked in a broad range of therapeutic areas including haematology, infectious diseases, oncology, ... psychiatric conditions, rare

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics